The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study. [electronic resource]
Producer: 20200608Description: 1-9 p. digitalISSN:- 1879-0852
- Antineoplastic Agents, Immunological -- adverse effects
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Biomarkers, Tumor -- genetics
- Breast Neoplasms -- drug therapy
- Chemotherapy, Adjuvant
- Clinical Decision-Making
- Clinical Trials, Phase III as Topic
- Female
- Gene Expression Profiling
- Humans
- Lapatinib -- adverse effects
- Multicenter Studies as Topic
- Neoadjuvant Therapy
- Patient Selection
- Precision Medicine
- Predictive Value of Tests
- Protein Kinase Inhibitors -- adverse effects
- Randomized Controlled Trials as Topic
- Receptor, ErbB-2 -- antagonists & inhibitors
- Retrospective Studies
- Risk Factors
- Time Factors
- Transcriptome
- Trastuzumab -- adverse effects
- Treatment Outcome
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.